Short answer
Celldex Therapeutics, Inc. (CLDX) filed an 8-K current report with the SEC on June 26, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved 3,400,000 additional shares for Celldex’s 2021 equity incentive plan.
Celldex Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stockholders approved 3,400,000 additional shares for Celldex’s 2021 equity incentive plan
- Expanded equity capacity supports employee and executive compensation but increases potential shareholder dilution
- Tax-withholding provisions clarified for awards under the plan
- Amendment effective June 25, 2026 following Annual Meeting approval
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All nine director nominees elected, supporting board continuity through the 2027 annual meeting
- PwC appointment ratified for fiscal year 2026, reducing near-term auditor-governance uncertainty
- Equity plan expanded by 3,400,000 shares to 12,900,000, increasing potential dilution capacity
- Executive compensation approved on an advisory basis, indicating shareholder support for current pay practices
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celldex Therapeutics, Inc. 8-K filings
Get the next CLDX 8-K as it lands
Follow CLDX for push alerts, or ask the research agent what this filing means.